ViiV Healthcare challenges three-drug HIV standard with positive Dovato VOGUE data
ViiV Healthcare’s VOGUE trial found Dovato non-inferior to Biktarvy at Week 48, sharpening the debate over two-drug first-line HIV care.
Pharma & Biotech